Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice

Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey

“…These biases might have produced the favorable survival in the present study. However, the patients in this study were prospectively registered with the company, and in particular, the actual 2-year survival rate of 33% seems to be markedly higher than we have ever experienced at our institution in clinical practice using other regimens [17,18]. In particular, most of the 2-year survivors in the present analysis had diffuse-type histology with peritoneal metastasis.…”

Retrospective analysis of clinical results and predictors of response in chemo-na�ve patients with advanced gastric cancer treated with S-1, an oral fluoropyrimidine derivative, as single-agent chemotherapy

“…In any case, it was clear that S-1 single-agent therapy was well-tolerated in the outpatient setting and that the frequency of severe toxicity in S-1 therapy might be lower than that seen in intravenous infusion treatment for patients with advanced gastric cancer in clinical practice [10].…”

“…As far as we know, no reports are currently available describing the hemoglobin level as a possible predictive factor for the clinical outcome in gastric cancer patients receiving chemotherapy [10,14,18]. Although the etiology is not well understood, anemia is a strong predictor of poorer survival in cancer patients with solid tumors or hematological malignancies [13,19].…”

“…The pretreatment variables examined were chosen by considering possible effects on the clinical course, as indicated by previous investigations [10][11][12][13], as well as those suggested from our own experience. The relationship of response to the following 11 categorized variables was studied: (1) Eastern Cooperative Oncology Group (ECOG) performance status (PS; 0 or 1); (2) histology (differentiated type or undifferentiated type); (3) macroscopic classification [9] (infiltrating type [type 4] or other types); (4) site of disease (classified as follows: primary lesion [present or absent]); (5) lymph node metastasis (present or absent); (6) liver metastasis (present or absent); (7) peritoneal disease, which included peritoneal dissemination and ascites (present or absent); (8) hemoglobin level (hemoglobin; male, м13.7 g/dl or Ͻ13.7 g/dl; female, м11.3 g/dl or Ͻ11.3 g/dl); (9) serum C-reactive protein (CRP; м1.0 mg/dl or Ͻ1.0 mg/dl); (10) serum lactate dehydrogenase (LDH; м230 U/l or Ͻ230 U/l); and (11) serum carcinoembryonic antigen (CEA; Ͼ5.0 ng/ml or Ϲ5.0 ng/ml).…”

Phase II and UGT1A1 Polymorphism Study of Two Different Irinotecan Dosages Combined with Cisplatin as First-Line Therapy for Advanced Gastric Cancer

“…Furthermore, some studies have reported irinotecan plus cisplatin (IP) as first-line chemotherapy for AGC with an ORR of 26-60% and OS of 6.9-16.7 months [6,7,8,9,10,11,12,13]. To the best of our knowledge, the optimal dose level of this regimen to improve efficacy along with minimal toxicity has not yet been established.…”